

For Immediate Release
Tuesday, May 17, 2011

Contact: Jessica Clark
850-222-1996

IRRISEPT Being Donated to Help Combat Infections in Storm-Ravaged Alabama

GAINESVILLE, FL – [IRRISEPT](#), a revolutionary new wound irrigation product, may play an important part in helping residents affected by the [storms](#) that recently ravaged the state of Alabama. The product is produced by IrriMax Corporation, a small Gainesville, FL based privately held company that recently introduced itself to the national healthcare market.

With only 12 employees, its CEO, Gareth Clarke, quickly learned that the devastation in Alabama had impacted family relatives of one of his own team.

“We may be a small company, but we recognize the need to help where we can during a time of need,” said Clarke. “We are pleased to donate IRRISEPT to affected communities and healthcare facilities in Alabama.”

IRRISEPT is the only FDA-cleared wound debridement and cleansing product containing [Chlorhexidine Gluconate, or CHG](#). Its pre-packaged delivery system makes it ideal for use in the clean up phase following natural disasters. In a situation where power outages, tainted water and rubble, among other hazards, pose health risks, the presence of CHG is significant because it is a proven antimicrobial and has been shown to be effective on bacteria and fungi, including Staph and MRSA.

The company has committed more than two thousand units of IRRISEPT to the Alabama disaster relief efforts. The [Alabama Hospital Association's](#) office of Government Relations and Emergency Preparedness is fielding requests for the product, which so far have resulted in product shipments directly to [Community Hospital](#) of Tallassee, Ala., and [JMC Health](#) in Jacksonville, Ala. The product also is being made available to public health workers and first responders.

About IrriMax Corporation

Founded in 1994, IrriMax® Corporation develops and markets wound irrigation solutions using a patented, innovative delivery method that produces unmatched efficacy and safety. The medical device company's goal is to improve patient outcomes by treating and preventing infections, as well as to increase the safety of healthcare workers. Its flagship product, IrriSept®, is the first and only FDA-cleared wound debridement and cleansing system containing CHG. Continual innovation and ongoing clinical research guide the development of IrriMax products. For more information, visit www.irrisept.com.